Statement: the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial.
Primary_evidence: INTERVENTION 1:    Treatment (Vorinostat, AI Therapy)   Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.   vorinostat: Given PO   anastrozole: Given PO   letrozole: Given PO   exemestane: Given PO   positron emission tomography: Correlative studies   F-18 16 alpha-fluoroestradiol: Correlative studies   fludeoxyglucose F 18: Correlative studies   laboratory biomarker analysis: Correlative studies
Secondary_evidence: INTERVENTION 1:    Fulvestrant 250 mg + Tipifarnib 300 mg   Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity